Table 2.

Response to pembrolizumab based on PFS with ipilimumab

Ipilimumab PFS
<90 days (n = 57)≥90 days (n = 59)P
ORR20 (35%)29 (49%)0.12
CBR26 (46%)39 (66%)0.03
<45 days (n = 12)≥180 days (n = 20)
ORR3 (25%)11 (55%)0.09
CBR3 (25%)16 (80%)0.002